bendamustine hydrochloride has been researched along with carfilzomib in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 4 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stewart, AK | 1 |
| Hata, H | 1 |
| Alsina, M; Anderson, KC; Bensinger, W; Biermann, JS; Cohen, AD; Devine, S; Djulbegovic, B; Faber, EA; Gasparetto, C; Hernandez-Illizaliturri, F; Huff, CA; Kassim, A; Krishnan, AY; Kumar, R; Liedtke, M; Meredith, R; Raje, N; Schriber, J; Shead, DA; Singhal, S; Somlo, G; Stockerl-Goldstein, K; Treon, SP; Weber, D; Yahalom, J; Yunus, F | 1 |
| Treon, SP | 1 |
| Hogan, JJ; Weiss, BM | 1 |
| Allen, J; Badillo, M; Lee, HJ; Ok, CY; Prabhu, V; Romaguera, JE; Sadimin, ET; Schalop, L; Schenkel, J; Tarapore, R; Wang, M; Zloza, A | 1 |
| Assal, A; Bhutani, D; Hu, J; Leng, S; Lentzsch, S; Mapara, M; Pan, S; Raza, S; Wei, A | 1 |
| Ai, WZ; Andreadis, CB; Aoun, C; Castillo, M; Cavallone, E; Crawford, E; Fakhri, B; Kambhampati, S; Kaplan, LD; Le, D; Martinelli, M; Padilla, M; Reiner, J; Sudhindra, A; Ta, T; Tuscano, JM; Wieduwilt, MJ | 1 |
| Badillo, M; Chen, W; Feng, L; Graham, V; Jain, P; Lee, HC; Lee, HJ; Lu, R; Manasanch, EE; Oriabure, O; Orlowski, RZ; Wang, ML | 1 |
| Aquino, S; Boccadoro, M; Corradini, P; Einsele, H; Engelhardt, M; Gay, F; Gentili, S; Gramatzki, M; Günther, A; Montefusco, V; Offidani, M; Palumbo, A; Patriarca, F; Pönisch, W; Salvini, M; Schub, N; Sonneveld, P; Spada, S; Straka, C; Wäsch, R | 1 |
3 review(s) available for bendamustine hydrochloride and carfilzomib
| Article | Year |
|---|---|
Novel therapies for relapsed myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Drug Screening Assays, Antitumor; Drugs, Investigational; Heat-Shock Proteins; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Mice; Mice, Transgenic; Multiple Myeloma; Neoplasm Proteins; Nitrogen Mustard Compounds; Oligopeptides; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Salvage Therapy; Thalidomide | 2009 |
[Development of novel agents for multiple myeloma; now and the future].
Topics: Animals; Antibodies, Monoclonal, Humanized; Bendamustine Hydrochloride; Benzoquinones; Benzylamines; Clinical Trials as Topic; Cyclams; Drug Discovery; Drug Therapy, Combination; Heterocyclic Compounds; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Molecular Targeted Therapy; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Thalidomide; Vorinostat | 2011 |
Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulins; Immunosuppressive Agents; Kidney Diseases; Lenalidomide; Melphalan; Oligopeptides; Paraproteinemias; Pentostatin; Rituximab; Thalidomide; Vidarabine | 2016 |
4 trial(s) available for bendamustine hydrochloride and carfilzomib
| Article | Year |
|---|---|
Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Prognosis | 2020 |
Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Diagnosis, Differential; Disease Management; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Oligopeptides; Prognosis; Recurrence; Retreatment; Rituximab; Treatment Outcome | 2021 |
A phase one trial of carfilzomib, bendamustine, and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Aged; Antineoplastic Agents; Bendamustine Hydrochloride; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Treatment Outcome | 2021 |
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides | 2021 |
3 other study(ies) available for bendamustine hydrochloride and carfilzomib
| Article | Year |
|---|---|
Multiple myeloma, version 1.2013.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Humans; Hydroxamic Acids; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Vorinostat | 2013 |
How I treat Waldenström macroglobulinemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Cyclophosphamide; Everolimus; Gene Expression; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin M; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Nitrogen Mustard Compounds; Oligopeptides; Piperidines; Plasmapheresis; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Sirolimus; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia | 2015 |
Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Dopamine D2 Receptor Antagonists; Doxorubicin; Drug Resistance, Neoplasm; Drug Substitution; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Male; Molecular Targeted Therapy; Neoplasm Proteins; Oligopeptides; Piperidines; Prednisone; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Rituximab; Stress, Physiological; Vincristine | 2019 |